On December 9, 2019 Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, reported the start of the first-in-human clinical trial of IMC-C103C, the third bispecific developed using the company’s innovative ImmTAC technology platform (Press release, Immunocore, DEC 9, 2019, View Source [SID1234552134]). IMC-C103C is focused on targeting tumours that express the protein MAGE-A4 (Melanoma-Associated Antigen A4) and is being developed in partnership with Genentech, a member of the Roche Group.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial (IMC-C103C-101) is designed to study the safety and preliminary activity of IMC-C103C as a monotherapy and in combination with atezolizumab (Tecentriq) in patients with MAGE-A4-expressing cancers.

David Berman, Head of Research and Development at Immunocore, commented: "We have now brought our third TCR- engineered bispecific ImmTAC into the clinic. IMC-C103C is designed to re-direct T cells to attack MAGE-A4 expressing tumours and we’re pleased to be moving its clinical development forward in partnership with Genentech."